Ultragenyx Pharmaceutical Inc. (RARE) stock
RARENasdaqPharmaceutical PreparationsFiscal year ends December 31
$16.70+0.80 (+5.03%)
Close on Nov 17, 2026Market cap $1.65BP/E –Yield –
Ultragenyx Pharmaceutical ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Ultragenyx Pharmaceutical's ebitda for the twelve months ending Jun 30, 2026 was -$495.17M. For fiscal 2025 it was -$500.00M. The highest annual figure on record is -$15.67M in fiscal 2012.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$500.00M | – |
| FY2024 | Dec 31, 2024 | -$500.00M | – |
| FY2023 | Dec 31, 2023 | -$543.00M | – |
| FY2022 | Dec 31, 2022 | -$630.70M | – |
| FY2021 | Dec 31, 2021 | -$368.50M | – |
| FY2020 | Dec 31, 2020 | -$317.86M | – |
| FY2019 | Dec 31, 2019 | -$415.63M | – |
| FY2018 | Dec 31, 2018 | -$351.84M | – |
| FY2017 | Dec 31, 2017 | -$323.12M | – |
| FY2016 | Dec 31, 2016 | -$244.58M | – |
| FY2015 | Dec 31, 2015 | -$146.35M | – |
| FY2014 | Dec 31, 2014 | -$56.09M | – |
| FY2013 | Dec 31, 2013 | -$31.84M | – |
| FY2012 | Dec 31, 2012 | -$15.67M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$67.00M | – |
| Q1 FY2026 | Mar 31, 2026 | -$161.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$104.50M | – |
| Q3 FY2025 | Sep 30, 2025 | -$162.68M | – |
| Q2 FY2025 | Jun 30, 2025 | -$99.00M | – |
| Q1 FY2025 | Mar 31, 2025 | -$134.00M | – |
| Q4 FY2024 | Dec 31, 2024 | -$112.77M | – |
| Q3 FY2024 | Sep 30, 2024 | -$123.23M | – |
| Q2 FY2024 | Jun 30, 2024 | -$107.50M | – |
| Q1 FY2024 | Mar 31, 2024 | -$156.50M | – |
| Q4 FY2023 | Dec 31, 2023 | -$113.63M | – |
| Q3 FY2023 | Sep 30, 2023 | -$137.91M | – |
| Q2 FY2023 | Jun 30, 2023 | -$142.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$148.87M | – |
| Q4 FY2022 | Dec 31, 2022 | -$140.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$220.37M | – |
| Q2 FY2022 | Jun 30, 2022 | -$137.11M | – |
| Q1 FY2022 | Mar 31, 2022 | -$132.54M | – |
| Q4 FY2021 | Dec 31, 2021 | -$99.03M | – |
| Q3 FY2021 | Sep 30, 2021 | -$86.61M | – |
| Q2 FY2021 | Jun 30, 2021 | -$79.66M | – |
| Q1 FY2021 | Mar 31, 2021 | -$103.20M | – |
| Q4 FY2020 | Dec 31, 2020 | -$92.95M | – |
| Q3 FY2020 | Sep 30, 2020 | -$47.22M | – |
| Q2 FY2020 | Jun 30, 2020 | -$59.87M | – |
| Q1 FY2020 | Mar 31, 2020 | -$117.81M | – |
| Q4 FY2019 | Dec 31, 2019 | -$92.28M | – |
| Q3 FY2019 | Sep 30, 2019 | -$115.89M | – |
| Q2 FY2019 | Jun 30, 2019 | -$110.37M | – |
| Q1 FY2019 | Mar 31, 2019 | -$97.10M | – |
| Q4 FY2018 | Dec 31, 2018 | -$87.40M | – |
| Q3 FY2018 | Sep 30, 2018 | -$85.29M | – |
| Q2 FY2018 | Jun 30, 2018 | -$88.82M | – |
| Q1 FY2018 | Mar 31, 2018 | -$90.33M | – |
| Q4 FY2017 | Dec 31, 2017 | -$94.32M | – |
| Q3 FY2017 | Sep 30, 2017 | -$82.62M | – |
| Q2 FY2017 | Jun 30, 2017 | -$77.39M | – |
| Q1 FY2017 | Mar 31, 2017 | -$68.79M | – |
| Q4 FY2016 | Dec 31, 2016 | -$69.39M | – |
| Q3 FY2016 | Sep 30, 2016 | -$64.75M | – |
See a number that looks wrong?